![Michael Shih](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Shih currently works at NeoPhore Ltd., as Chief Executive Officer & Director from 2024.
Mr. Shih also formerly worked at Kite Pharma, Inc., as Vice President-Corporate Development.
| Unternehmen | Position | Beginn |
|---|---|---|
NeoPhore Ltd.
 NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of small molecules inhibitors to treat cancer | Vorstandsvorsitzender | 16.12.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| KITE PHARMA INC | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 2 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
NeoPhore Ltd.
NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of small molecules inhibitors to treat cancer | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
Wählen Sie MarketScreener 
